(AOF) – Eurobio Scientific records a turnover of 130 million euros for the 2023 financial year, down 17%. The gross operating margin rate, before the non-recurring effect of the sale of GenDx stocks allocated under the PPA (purchase price allocation), increases to 47.6% in 2023, compared to 46.7 % last year. Its 2023 net profit fell by 81% to 4.8 million euros. Its operating profit also decreased from 30.8 million euros in 2022 to 10.1 million euros in 2023.
At the end of December 2023, Eurobio Scientific has cash of 89 million euros, for a financial debt (excluding leasing) of 94.5 million euros, i.e. a net financial debt of 5.5 million euros, compared to 22 million euros a year earlier.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.